Risperidone for the treatment of neuropsychiatric features in dementia

Drugs and Aging

Volumn 23, Issue 11, 2006, Pages 887-896

  Burns, Alistair ^a   De Deyn, Peter P ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; ZIPRASIDONE;

AGITATION; AKATHISIA; ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DEMENTIA; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPERLIPIDEMIA; META ANALYSIS; MORTALITY; MULTIINFARCT DEMENTIA; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPSYCHIATRY; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PERIPHERAL EDEMA; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; URINE RETENTION; VISUAL DISORDER; WEIGHT GAIN; XEROSTOMIA;

ACCIDENTAL FALLS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CEREBROVASCULAR DISORDERS; COGNITION DISORDERS; DEMENTIA; HUMANS; RISPERIDONE;

EID: 33751254048     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623110-00004     Document Type: Review

References (79)

1. Hendrie HC. Epidemiology of dementia and Alzheimer's disease. Am J Geriatr Psychiatry 1998; 6 (2 Suppl. 1): S3-18
2. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989; 262: 2551-6
3. Hemels ME, Lanctot KL, Iskedjian M, et al. Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia. Drugs Aging 2001; 18: 527-50
4. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. I: disorders of thought content. Br J Psychiatry 1990; 157: 72-94
5. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14
6. Finkel SI, Costa e Silva J, Cohen G, et al. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 1996; 8 Suppl. 3: 497-500
7. Jeste DV, Finkel SI. Psychosis of Alzheimer's disease and related dementias: diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000; 8: 29-34
8. Donaldson C, Tarrier N, Burns A. The impact of the symptoms of dementia on caregivers. Br J Psychiatry 1997; 170: 62-8
9. Burns A, Lawlor B, Craig S. Assessment scales in old age psychiatry. 2nd ed. London: Taylor & Francis, 2004
10. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987 May; 48 (Suppl. 5): 9-15
11. Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000; 12: 233-9
12. Cohen-Mansfield J. Conceptualization of agitation: results based on the Cohen-Mansfield agitation inventory and the agitation behavior mapping instrument. Int Psychogeriatr 1996; 8 Suppl. 3: 309-15
13. Brodaty H, Draper B, Saab D, et al. Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors. Int J Geriatr Psychiatry 2001; 16: 504-12
14. Ballard CG, Margallo-Lana M, Fossey J, et al. A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J Clin Psychiatry 2001; 62: 631-6
15. Tractenberg RE, Weiner MF, Thal LJ. Estimating the prevalence of agitation in community-dwelling persons with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2002; 14: 11-8
16. Haupt M, Kurz A, Janner M. A 2-year follow-up of behavioural and psychological symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord 2000; 11: 147-52
17. Haupt M, Janner M, Ebeling S, et al. Presentation and stability of noncognitive symptom patterns in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12: 323-9
18. Rapoport MJ, van Reekum R, Freedman M, et al. Relationship of psychosis to aggression, apathy and function in dementia. Int J Geriatr Psychiatry 2001; 16: 123-30
19. Engelborghs S, Maertens K, Nagels G, et al. Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. Int J Geriatr Psychiatry 2005; 20: 1028-37
20. Lawton MP. Assessing quality of life in Alzheimer disease research. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 6: 91-9
21. Tarrier N, Barrowclough C, Ward J, et al. Expressed emotion and attributions in the carers of patients with Alzheimer's disease: the effect on carer burden. J Abnorm Psychol 2002; 111: 340-9
22. Tariot PN. Clinical effectiveness of atypical antipsychotics in dementia. J Clin Psychiatry 2004; 65 Suppl. 11: 3-4
23. Burns A, Byrne J, Ballard C, et al. Sensory stimulation in dementia. BMJ 2002; 325: 1312-3
24. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc 2003; 51: 1305-17
25. Schneider LS, Pollock VE, Lyness SA. A meta analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553-63
26. Jeste DV, Rockwell E, Harris MJ, et al. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 1999; 7: 70-6
27. Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000; 93: 457-62
28. Zaudig M. A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia. Drug Saf 2000; 23: 183-95
29. McShane R, Keene J, Gedling K, et al. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ 1997; 314: 266-70
30. Lawlor B, Bhriain SN. Psychosis and behavioural symptoms of dementia: defining the role of neuroleptic interventions. Int J Geriatr Psychiatry 2001; 16 Suppl. 1: S2-6
31. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946-55
32. Liperoti R, Mor V, Lapane KL, et al. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003; 64: 1106-12
33. Alexopoulos GS, Jeste DV, Chung H, et al. The Expert Consensus Guideline Series: treatment of dementia and its behavioral disturbances. Postgrad Med Special Report 2005 Jan: 1-111
34. Greve M, O'Connor D. A survey of Australian and New Zealand old age psychiatrists' preferred medications to treat behavioural and psychological symptoms of dementia (BPSD). Int Psychogeriatr 2005; 17: 195-205
35. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60: 107-15
36. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000; 57: 968-76
37. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: 134-43
38. Schneider LS, Tariot PN, Lyketsos CG, et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry 2001; 9: 346-60
39. Risperdal® (risperidone) [package insert]. Titusville (NJ): Janssen Pharmaceutica Products LP, 2005 May
40. Chan WC, Lam LC, Choy CN, et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001; 16: 1156-62
41. Rainer MK, Masching AJ, Ertl MG, et al. Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. J Clin Psychiatry 2001; 62: 894-900
42. Laks J, Engelhardt E, Marinho V, et al. Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly. Arq Neuropsiquiatr 2001; 59: 859-64
43. Lavretsky H, Sultzer D. A structured trial of risperidone for the treatment of agitation in dementia. Am J Geriatr Psychiatry 1998; 6: 127-35
44. Frenchman IB, Prince T. Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances. Int Psychogeriatr 1997; 9: 431-5
45. Irizarry MC, Ghaemi SN, Lee-Cherry ER, et al. Risperidone treatment of behavioral disturbances in outpatients with dementia. J Neuropsychiatry Clin Neurosci 1999; 11: 336-42
46. Yoon JS, Kim JM, Lee H, et al. Risperidone use in Korean patients with Alzheimer's disease: optimal dosage and effect on behavioural and psychological symptoms, cognitive function and activities of daily living. Hum Psychopharmacol 2003; 18: 627-33
47. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157: 1150-5
48. De Deyn PP, Katz IR, Brodaty H, et al. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg 2005; 107: 497-508
49. Mintzer J, Greenspan A, Caers I, et al. Risperidone in the treatment of psychosis of Alzheimer's disease: results from a prospective clinical trial. Am J Geriatr Psychiatry 2006; 14: 280-91
50. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002; 167: 1269-70
51. Suh GH, Son HG, Ju YS, et al. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry 2004; 12: 509-16
52. De Deyn PP, Wirshing WC. Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. J Clin Psychiatry 2001; 62 Suppl. 21: 19-22
53. Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. Int Psychogeriatr 1997; 9: 65-8
54. Arriola E, Diago JI. Treatment with risperidone: positive impact on patients with BPSD and caregiver stress. Am J Geriatr Pharmacother 2005; 3: 8-16
55. Wancata J. Efficacy of risperidone for treating patients with behavioral and psychological symptoms of dementia. Int Psychogeriatr 2004; 16: 107-15
56. Schwalen S, Kurz A. Risperidone for the treatment of behavioural disorders in dementia. Nervenheilkunde 2002; 21: 208-13
57. Shigenobu K, Ikeda M, Fukuhara R, et al. Reducing the burden of caring for Alzheimer's disease through the amelioration of "delusions of theft" by drug therapy. Int J Geriatr Psychiatry 2002; 17: 211-7
58. Lane HY, Chang YC, Su MH, et al. Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects. J Clin Psychopharmacol 2002; 22: 4-10
59. De Deyn PP, Katz IR. Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone. Int J Geriatr Psychiatry 2000; 15 Suppl. 1: S14-22
60. Alexopoulos GS, Streim J, Carpenter D, et al. Using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65 Suppl. 2: 5-99
61. Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65: 464-70
62. Mion LC, Gregor S, Buettner M, et al. Falls in the rehabilitation setting: incidence and characteristics [published erratum appears in Rehabil Nurs 1989; 14: 133]. Rehabil Nurs 1989; 14: 17-22
63. Kiely DK, Kiel DP, Burrows AB, et al. Identifying nursing home residents at risk for falling. J Am Geriatr Soc 1998; 46: 551-5
64. Marx MS, Cohen-Mansfield J, Werner P. Agitation and falls in institutionalized elderly persons. J Appl Gerontol 1990; 9: 106-17
65. Katz IR, Rupnow M, Kozma C, et al. Risperidone and falls in ambulatory nursing home residents with dementia and psychosis or agitation: secondary analysis of a double-blind, placebo-controlled trial. Am J Geriatr Psychiatry 2004; 12: 499-508
66. Martin H, Slyk MP, Deymann S, et al. Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia [published erratum appears in J Am Med Dir Assoc 2003; 4: 290]. J Am Med Dir Assoc 2003; 4: 183-8
67. Greenspan A, Eerdekens M, Mahmoud R. Risk of cerebrovascular adverse events, including mortality, with risperidone in elderly patients. Int Psychogeriatr 2003; PB-041 Suppl. 2: 261-2
68. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004; 170: 1395
69. Committee on the Safety of Medicines. Atypical antipsychotic drugs and stroke: message from Professor Gordon Duff, Chairman, Committee on Safety of Medicines (CEM/CMO/2004/1). London: Medicines and Healthcare products Regulatory Agency [online]. Available from URL: http://www.mca.gov.uk/ourwork/ monitorsafequalmed/safetymessages/antipsystroke_9304.htm [Accessed 2005 May 5]
70. Abilify™ (aripiprazole) tablets. FDA [online]. Available at URL: http://www.fda.gov/medwatch/SAFETY/2004/apr_PI/Abilify_PI.pdf [Accessed 2005 May 5]
71. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330: 445
72. Finkel S, Kozma C, Long S, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr 2005; 17: 617-29
73. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113-5
74. FDA issues public health advisory for antipsychotic drugs used for treatment of behavioral disorders in elderly patients. FDA [online]. Available at URL: http://www.fda.gov/bbs/topics/ANSWERS/2005/ANS01350.html [Accessed 2005 Apr 11]
75. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-43
76. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353: 2335-41
77. Katz IR, Brodaty H, De Deyn PP, et al. Risperidone in the treatment of psychosis of Alzheimer's disease (PAD): a pooled analysis of 4 controlled trials. Poster presented at the annual scientific meeting of the American Geriatrics Society (AGS); 2005 May 11-15; Orlando (Florida), USA
78. Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004; 329: 75-9
79. The UK Royal College of Psychiatrists. Atypical antipsychotics and behavioural and psychiatric symptoms of dementia. Prescribing update for old age psychiatrists. London: The Royal College of Psychiatrists [online]. Available from URL: http://www.rcpsych.ac.uk/college/faculty/oap/BPSD.pdf [Accessed 2005 Nov 1]